EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial

Raúl Moreno, José Souza, Rüdiger Smolnik, Luis Nombela-Franco, Nicolas M Van Mieghem, Christian Hengstenberg, Marco Valgimigli, James Jin, Patrick Ohlmann, George Dangas, Martin Unverdorben, Helge Möllmann

Clinical Research in Cardiology · 2025

DOI: 10.1007/s00392-024-02379-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Raúl Moreno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Cardiology, University Hospital La Paz, Paseo La Castellana, 261, 28046, Madrid, Spain. raulmorenog@hotmail.com. Hauptthemen laut MEDLINE: Atrial Fibrillation, Transcatheter Aortic Valve Replacement, Percutaneous Coronary Intervention, Aortic Valve Stenosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with atrial fibrillation (AF) and a recent (≤ 90 days) percutaneous coronary intervention (PCI) undergoing transcatheter aortic valve implantation (TAVI) are at high bleeding risk due to the addition of oral antiplatelet (OAP) agents on top of oral anticoagulants. Data on outcomes of these patients are needed to optimize antithrombotic treatment.

Methods

This analysis compared annualized clinical event rates in patients with and without a recent PCI enrolled in ENVISAGE-TAVI AF, a prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban and vitamin K antagonists in AF patients after TAVI. The primary efficacy and safety outcomes were net adverse clinical events (NACE) and major bleeding.

Results

Overall, 132 (94.3%) patients with a recent PCI ( n = 140) received OAP after TAVI, compared with 692 (55.9%) patients without a recent PCI ( n = 1237). Among patients with a recent PCI on OAP agents, use of dual antiplatelet therapy decreased to 5.5%, and use of single antiplatelet therapy (SAPT) increased to 78.0% over 3 months post-randomization. Conversely, use of SAPT predominated at all time points in patients without a recent PCI history. There were no significant differences in the incidence of NACE or other outcomes assessed, except for major bleeding events, which were more frequent in patients with vs without a recent PCI history (hazard ratio [95% confidence interval]: 2.17 [1.27, 3.73]; P = 0.005).

Conclusions

Patients with AF undergoing TAVI with a recent PCI have a similar risk of ischemic events and mortality, but an increased risk of major bleeding compared with patients without a recent PCI. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationTranscatheter Aortic Valve ReplacementPercutaneous Coronary InterventionAortic Valve StenosisPlatelet Aggregation InhibitorsPyridinesThiazolesHumansMaleFemaleAged, 80 and overProspective StudiesAgedTreatment OutcomeHemorrhageRisk FactorsAnticoagulantsFactor Xa InhibitorsAdministration, OralTime FactorsFollow-Up Studies

Stichwörter der Autor:innen

Antiplatelet therapyAtrial fibrillationEdoxabanPercutaneous coronary interventionTranscatheter aortic valve replacement

Substanzen

Platelet Aggregation InhibitorsPyridinesedoxabanThiazolesAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Interventional Cardiology, University Hospital La Paz, Paseo La Castellana, 261, 28046, Madrid, Spain. raulmorenog@hotmail.com.
  • Daiichi Sankyo, Inc., Munich, Germany.
  • Interventional Cardiology, Hospital Clinico San Carlos, Madrid, Spain.
  • Department of Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam, the Netherlands.
  • Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University, Vienna, Austria.
  • Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Università Della Svizzera Italiana (USI) and University of Berne, Berne, Switzerland.

Förderung

  • Daiichi Sankyo, Inc

Zitieren

APA

Moreno, R., Souza, J., Smolnik, R., Nombela-Franco, L., Van Mieghem, N. M., Hengstenberg, C., Valgimigli, M., Jin, J., Ohlmann, P., Dangas, G., Unverdorben, M., & Möllmann, H. (2025). Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02379-5

Vancouver

Moreno R, Souza J, Smolnik R, Nombela-Franco L, Van Mieghem NM, Hengstenberg C, et al. Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-024-02379-5

BibTeX
@article{Moreno2025,
  author = {Moreno, Raúl and Souza, José and Smolnik, Rüdiger and Nombela-Franco, Luis and Van Mieghem, Nicolas M and Hengstenberg, Christian and Valgimigli, Marco and Jin, James and Ohlmann, Patrick and Dangas, George and Unverdorben, Martin and Möllmann, Helge},
  title = {Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  doi = {10.1007/s00392-024-02379-5}
}
Kostenlos starten →